Inspire Medical Systems, Inc. (NYSE:INSP – Get Free Report) has been given a consensus rating of “Hold” by the twenty ratings firms that are covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $68.82.
INSP has been the topic of a number of recent analyst reports. Evercore set a $54.00 price target on shares of Inspire Medical Systems in a research report on Tuesday, August 4th. Oppenheimer raised shares of Inspire Medical Systems from a “market perform” rating to an “outperform” rating and set a $85.00 price objective for the company in a report on Tuesday, August 4th. KeyCorp reiterated a “sector weight” rating on shares of Inspire Medical Systems in a research note on Tuesday, August 4th. JPMorgan Chase & Co. lifted their target price on shares of Inspire Medical Systems from $54.00 to $60.00 and gave the company a “neutral” rating in a research note on Tuesday, August 4th. Finally, Piper Sandler boosted their target price on Inspire Medical Systems from $55.00 to $60.00 and gave the stock a “neutral” rating in a report on Tuesday, August 4th.
View Our Latest Research Report on Inspire Medical Systems
Insiders Place Their Bets
In other Inspire Medical Systems news, insider Jason Kelly sold 963 shares of Inspire Medical Systems stock in a transaction on Friday, August 7th. The stock was sold at an average price of $59.55, for a total value of $57,346.65. Following the completion of the transaction, the insider owned 18,985 shares in the company, valued at approximately $1,130,556.75. The trade was a 4.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.20% of the stock is owned by corporate insiders.
Institutional Trading of Inspire Medical Systems
Several large investors have recently made changes to their positions in the business. EverSource Wealth Advisors LLC increased its stake in shares of Inspire Medical Systems by 1,115.4% in the first quarter. EverSource Wealth Advisors LLC now owns 632 shares of the company’s stock valued at $33,000 after buying an additional 580 shares in the last quarter. Versant Capital Management Inc lifted its position in Inspire Medical Systems by 379.0% during the 2nd quarter. Versant Capital Management Inc now owns 958 shares of the company’s stock worth $43,000 after buying an additional 758 shares in the last quarter. GAMMA Investing LLC lifted its position in Inspire Medical Systems by 85.0% during the 2nd quarter. GAMMA Investing LLC now owns 1,221 shares of the company’s stock worth $54,000 after buying an additional 561 shares in the last quarter. Sterling Capital Management LLC lifted its position in Inspire Medical Systems by 450.6% during the 3rd quarter. Sterling Capital Management LLC now owns 914 shares of the company’s stock worth $63,000 after buying an additional 748 shares in the last quarter. Finally, State of Wyoming lifted its position in Inspire Medical Systems by 83.7% during the 1st quarter. State of Wyoming now owns 1,343 shares of the company’s stock worth $69,000 after buying an additional 612 shares in the last quarter. Institutional investors own 94.91% of the company’s stock.
Inspire Medical Systems Stock Performance
Shares of NYSE:INSP opened at $68.02 on Monday. The company’s fifty day moving average is $68.59 and its 200-day moving average is $58.94. Inspire Medical Systems has a 52 week low of $38.91 and a 52 week high of $147.03. The company has a market capitalization of $1.97 billion, a PE ratio of 14.72, a P/E/G ratio of 5.15 and a beta of 0.67.
Inspire Medical Systems (NYSE:INSP – Get Free Report) last announced its earnings results on Monday, August 3rd. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.38. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The business had revenue of $200.58 million during the quarter, compared to analysts’ expectations of $194.72 million. During the same quarter last year, the company posted $0.45 EPS. The firm’s revenue for the quarter was down 7.6% on a year-over-year basis. On average, analysts forecast that Inspire Medical Systems will post 1.24 EPS for the current year.
About Inspire Medical Systems
Inspire Medical Systems, Inc develops and commercializes medical devices for the treatment of obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly narrows or becomes blocked during sleep. The company’s primary product is Inspire therapy, an implantable system designed to help keep the airway open by stimulating the hypoglossal nerve, which controls muscles involved in maintaining airway patency.
Inspire therapy is intended for certain adults with moderate to severe OSA who are unable to use or obtain consistent benefit from continuous positive airway pressure (CPAP) therapy.
Featured Stories
- Five stocks we like better than Inspire Medical Systems
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
- Exxon’s Refining Profits Soared—Did Chevron Get the Same Windfall?
- Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?
- Oracle’s AI Spending Peak Is in Sight—Can the Stock Recover?
Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.
